Ariad storms back with an FDA nod to get Iclusig back on the U.S. market

Damian Garde Losing more than $ 2.5 billion in market value didn't kill Ariad Pharmaceuticals, and now the biotech is set to relaunch the once-spurned cancer drug Iclusig in the ...

Daiichi’s a-fib drug aces PhIII, faces crowded market

Damian Garde Daiichi Sankyo's atrial fibrillation-treating edoxaban posted promising results in Phase III, matching the stroke-prevention prowess of warfarin with a better safety ...

Bayer envisions bigger Eylea market with new EU use

Tracy Staton Bayer has taken another step toward fulfilling blockbuster ambitions for its eye drug Eylea. The German drugmaker asked European regulators to approve the vision-loss treatment ...

FDA helps generic drugmakers get copies of Glaxo’s Advair to market

Carly Helfand GlaxoSmithKline's Advair is hard to copy. Some companies have given up on generic Advair, while others have shied away altogether despite the substantial sales up ...

Roche’s Rituxan successor first up in market scramble for first-line treatment of CLL

Eric Palmer A number of drugmakers have been looking to get drugs across the finish line for approval of first-line use in the treatment of chronic lymphocytic leukemia, and Roche's ...

GlobeImmune pulls plug on $75M IPO despite still-bubbling market

Damian Garde After repeated delays, Colorado immunotherapy developer GlobeImmune has finally called it quits on plans to raise up to $ 74.8 million in an IPO, citing poor market conditions ...

Cancer immunotherapies set to storm onto the market, analysts say

Tracy Staton Over the past year the excitement in biopharma R&D circles about the therapeutic punch of cancer immunotherapies has reached fever pitch, and the intense ...

Vital Therapies plots $86M IPO as biotech market boils

Damian Garde San Diego's Vital Therapies has filed for an $ 86.3 million IPO, eyeing a piece of the burgeoning market for biotechs on Wall Street as it advances a novel treatment ...

Celladon, Xencor bid for $155M in red-hot IPO market

Damian Garde Celladon and Xencor have cast lines into the still-blazing biotech IPO scene, seeking a combined $ 155.3 million and betting that the recent Wall Street excitement for ...

Vertex asks FDA to expand market for CF drug Kalydeco

Tracy Staton Vertex Pharmaceuticals asked the FDA to approve broader use of its cystic fibrosis drug Kalydeco. Already marketed for patients with a G551 "gateway" mutation, ...

Boehringer’s China expansion hits as probes leave market in turmoil

Eric Palmer Germany's Boehringer Ingelheim two years ago started on a major addition to its operations in China as that rapidly expanding market looked like the promised land to ...

Africa’s growing market attracts Hikma to Ethiopia

Eric Palmer South Africa has a well-established pharmaceutical industry, and North Africa is attracting more attention from Western drugmakers. But many countries in between have limited ...
Page 3 of 812345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS